Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

VRCA

Verrica Pharmaceuticals Inc

Nov 27 • 04:00PM ET

1.24

Dollar change +0.13
Percentage change 11.71	%

Healthcare • Biotechnology • USA • NASD

Peers: DERM HRTX ACRS SUPN CLSD KPTI XERS ADMA DMAC EYPT

| Held by: VTI IWM VXF IWO VTWO IWC VTWG RSSL UWM URTY

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.83	Insider Own	40.33%	Shs Outstand	42.41M	Perf Week	39.73%
Market Cap	125.45M	Forward P/E	-	EPS next Y	-0.68	Insider Trans	-0.67%	Shs Float	27.21M	Perf Month	-26.19%
Income	-84.99M	PEG	-	EPS next Q	-0.30	Inst Own	32.75%	Short Float	16.58%	Perf Quarter	-49.18%
Sales	9.21M	P/S	13.62	EPS this Y	-3.55%	Inst Trans	-17.73%	Short Ratio	4.70	Perf Half Y	-85.11%
Book/sh	-0.75	P/B	-	EPS next Y	55.79%	ROA	-130.68%	Short Interest	4.51M	Perf Year	-66.84%
Cash/sh	0.23	P/C	5.46	EPS next 5Y	-	ROE	-2059.89%	52W Range	0.70 - 11.41	Perf YTD	-83.06%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-0.97%	ROI	-714.15%	52W High	-89.13%	Beta	1.37
Dividend TTM	-	Quick Ratio	1.22	Sales past 5Y	-13.60%	Gross Margin	72.90%	52W Low	76.06%	ATR (14)	0.15
Dividend Ex-Date	-	Current Ratio	1.34	EPS Y/Y TTM	-69.90%	Oper. Margin	-812.68%	RSI (14)	54.83	Volatility	15.38% 13.67%
Employees	100	Debt/Eq	-	Sales Y/Y TTM	187.45%	Profit Margin	-922.81%	Recom	2.60	Target Price	3.50
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	9.27%	Payout	-	Rel Volume	1.94	Prev Close	1.11
Sales Surprise	-133.85%	EPS Surprise	-30.22%	Sales Q/Q	-161.06%	Earnings	Nov 04 AMC	Avg Volume	959.41K	Price	1.24
SMA20	24.92%	SMA50	-5.00%	SMA200	-74.83%	Trades		Volume	1,861,689	Change	11.71%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

Nov-21-24 07:30AM	Verrica Announces Pricing of $42.0 Million Public Offering (GlobeNewswire) +11.56%
Nov-20-24 04:05PM	Verrica Announces Proposed Public Offering (GlobeNewswire)
Nov-04-24 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition (GlobeNewswire) -6.54% -44.23%
Oct-24-24 07:00AM	Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-09-24 06:21PM	Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
07:30AM	Loading…
Oct-02-24 07:30AM	Verrica Pharmaceuticals Announces Restructuring of Commercial Organization (GlobeNewswire) -18.98%
Sep-29-24 08:02AM	Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:27AM	Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? (Insider Monkey) -5.68%
Sep-20-24 05:21AM	Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) (Newsfile) -6.70%
Sep-04-24 07:30AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York (GlobeNewswire) +5.50%
Aug-15-24 07:32AM	Verrica stock drops after half patients tumours gone in skin cancer trial (Clinical Trials Arena) -6.73%
Aug-14-24 09:52AM	Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -40.80%
08:55AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma (GlobeNewswire)
07:30AM	Loading…
Aug-06-24 07:30AM	Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 (GlobeNewswire) -5.45%
Jul-15-24 11:57AM	7 Short-Squeeze Stocks That Could Beat Down the Bears (InvestorPlace)
Jul-01-24 07:30AM	Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. (GlobeNewswire) +9.05%
May-30-24 04:30PM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)
08:40AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
07:30AM	Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results (GlobeNewswire)
May-09-24 07:30AM	Verrica Pharmaceuticals to Present at Upcoming Investor Conferences (GlobeNewswire)
May-08-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024 (GlobeNewswire)
06:35AM	Loading…
May-06-24 06:35AM	Verrica Pharmaceuticals (VRCA) Moves 7.4% Higher: Will This Strength Last? (Zacks)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-02-24 07:30AM	Verrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-24 07:30AM	Verrica Pharmaceuticals Announces that YCANTH Receives New Chemical Entity Status and Orange Book Listing from the FDA (GlobeNewswire) +5.14%
Mar-01-24 09:10AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q4 2023 Earnings Call Transcript (Insider Monkey) +5.31%
Feb-29-24 08:11AM	Verrica Pharmaceuticals Inc (VRCA) Reports Fourth Quarter and Full-Year 2023 Financial Results (GuruFocus.com) -7.87%
07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results (GlobeNewswire)
Feb-27-24 07:30AM	Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference (GlobeNewswire)
Feb-22-24 07:30AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024 (GlobeNewswire)
Feb-05-24 07:30AM	Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition (GlobeNewswire) -7.58%
Jan-29-24 07:30AM	Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH from Centers for Medicare and Medicaid Services (GlobeNewswire)
Jan-22-24 07:44PM	7 Potential Short-Squeeze Stocks Poised for Rapid Gains (InvestorPlace)
Jan-05-24 07:30AM	Verrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Jan-04-24 07:30AM	Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH for the Treatment of Common Warts (GlobeNewswire)
Jan-03-24 07:30AM	Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH (GlobeNewswire)
Dec-15-23 01:49PM	Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today? (InvestorPlace) +61.97%
06:00AM	Verrica Pharmaceuticals' Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-11-23 10:13AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-10-23 08:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-09-23 07:30AM	Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results (GlobeNewswire) -9.83%
Oct-25-23 07:00AM	Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023 (GlobeNewswire)
Sep-27-23 08:00AM	Verrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023 (GlobeNewswire)
Aug-31-23 08:00AM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-24-23 08:30AM	Verrica Pharmaceuticals Announces First Sale of YCANTH to FFF Enterprises (GlobeNewswire)
Aug-23-23 07:30AM	Verrica Issues Statement in Support of FDAs Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum (GlobeNewswire)
Aug-10-23 04:05PM	Verrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Aug-08-23 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2023 Financial Results (GlobeNewswire)
Aug-03-23 07:30AM	Verrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Associations (AAD) 2023 Innovation Academy Meeting (GlobeNewswire)
Jul-27-23 06:06AM	Verrica Pharmaceuticals Chairman of the Board Acquires 1.3% More Stock (Simply Wall St.)
Jul-26-23 04:05PM	Verrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed (GlobeNewswire)
Jul-25-23 07:16AM	Daily Vickers Top Buyers & Sellers for 07/25/2023 (Argus Research)
Jul-24-23 03:16PM	Why Shares of Verrica Pharmaceuticals Are Plummeting on Monday (Motley Fool) -31.46%
07:00AM	Following FDA Approval of YCANTH for the Treatment of Molluscum Contagiosum, Verrica Pharmaceuticals Enters into Non-Binding Term Sheet for up to $125 Million Debt Financing; Company to Host Conference Call and Webcast This Morning at 8:30 am ET (GlobeNewswire)
Jul-21-23 04:47PM	UPDATE 2-Verrica's drug gets US nod as first treatment for a type of skin infection (Reuters)
04:30PM	US FDA approves Verrica's skin disease treatment (Reuters)
04:24PM	Verrica Pharmaceuticals Announces FDA Approval of YCANTH (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum (GlobeNewswire)
Jul-17-23 07:22AM	With a 39% stake, Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have a lot riding on the company (Simply Wall St.) +6.43%
Jul-12-23 03:16AM	Net Asset Value(s) (Business Wire)
May-31-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York (GlobeNewswire) +6.58%
May-30-23 12:34PM	We're Not Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn (Simply Wall St.) -7.48%
May-10-23 07:30AM	Verrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference (GlobeNewswire)
06:11AM	Verrica Pharmaceuticals First Quarter 2023 Earnings: EPS Beats Expectations, Revenues Lag (Simply Wall St.)
May-09-23 07:30AM	Verrica Pharmaceuticals Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-05-23 09:07AM	The past three years for Verrica Pharmaceuticals (NASDAQ:VRCA) investors has not been profitable (Simply Wall St.)
Apr-26-23 08:01PM	7 Biotech Stocks With Huge Return Potential for Long-Term Investors (InvestorPlace)
Apr-12-23 07:00AM	Verrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma (GlobeNewswire)
Apr-11-23 07:00AM	Verrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-06-23 07:30AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results (GlobeNewswire)
Feb-28-23 04:05PM	Verrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference (GlobeNewswire)
Feb-27-23 04:05PM	Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire) -5.47%
Feb-22-23 11:49AM	Verrica Pharmaceuticals expects $32.5M from the sale of stock and warrants (American City Business Journals)
Feb-21-23 07:22AM	Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (GlobeNewswire) +5.56%
Feb-17-23 06:43PM	12 Most Promising Micro-Cap Stocks According to Analysts (Insider Monkey) +8.34%
Feb-14-23 10:15AM	2 Breakout Growth Stocks to Buy for the Long Haul (Motley Fool)
Jan-24-23 07:30AM	Verrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum (GlobeNewswire)
07:16AM	Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) insiders have significant skin in the game with 40% ownership (Simply Wall St.)
Jan-04-23 07:30AM	Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions (GlobeNewswire) +14.93%
Jan-01-23 08:16AM	Bullish insiders bet US$11m on Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) (Simply Wall St.)
Dec-12-22 12:07PM	We're Not Very Worried About Verrica Pharmaceuticals' (NASDAQ:VRCA) Cash Burn Rate (Simply Wall St.)
Nov-26-22 07:00AM	Investors in Verrica Pharmaceuticals (NASDAQ:VRCA) have unfortunately lost 83% over the last three years (Simply Wall St.)
Nov-07-22 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.72%
Aug-31-22 04:30PM	Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire) +8.89%
Aug-17-22 07:53AM	Is Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) Popular Amongst Insiders? (Simply Wall St.)
Aug-11-22 07:30AM	Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results (GlobeNewswire) +5.22%
Aug-04-22 01:38PM	Zoetis' (ZTS) Q2 Earnings Miss Estimates, Revenues Up (Zacks)
12:34PM	Pacira's (PCRX) Q2 Earnings Miss Estimates, Revenues Rise Y/Y (Zacks)
Aug-03-22 12:02PM	United Therapeutics (UTHR) Q2 Earnings Miss Estimates, Revenues Up (Zacks)
Aug-01-22 07:30AM	Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan (GlobeNewswire) -6.35%
Jul-20-22 12:00PM	Verrica Pharmaceuticals Inc. (VRCA) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +5.61%
Jul-18-22 11:43AM	Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada (Zacks)

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Hayes Christopher G.	CHIEF LEGAL OFFICER	Aug 26 '24	Sale	2.66	26,183	69,647	115,303	Aug 28 04:15 PM
Hayes Christopher G.	CHIEF LEGAL OFFICER	Aug 27 '24	Sale	2.46	9,530	23,444	105,773	Aug 28 04:15 PM
Goldenberg Gary	Chief Medical Officer	Aug 26 '24	Sale	2.66	9,888	26,302	97,862	Aug 28 04:15 PM
Goldenberg Gary	Chief Medical Officer	Aug 27 '24	Sale	2.46	3,601	8,858	94,261	Aug 28 04:15 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Aug 26 '24	Sale	2.66	24,709	65,726	82,107	Aug 28 04:15 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Aug 27 '24	Sale	2.46	8,993	22,123	73,114	Aug 28 04:15 PM
Kohler Terry	CHIEF FINANCIAL OFFICER	Aug 26 '24	Sale	2.66	21,820	58,041	52,596	Aug 28 04:15 PM
Kohler Terry	CHIEF FINANCIAL OFFICER	Aug 27 '24	Sale	2.46	7,899	19,432	44,697	Aug 28 04:15 PM
White Ted	PRESIDENT AND CEO	Aug 26 '24	Sale	2.66	24,979	66,444	224,988	Aug 28 04:15 PM
White Ted	PRESIDENT AND CEO	Aug 27 '24	Sale	2.46	9,021	22,192	215,967	Aug 28 04:15 PM
Hayes Christopher G.	Officer	Aug 26 '24	Proposed Sale	2.62	36,000	94,300		Aug 26 04:45 PM
Goldenberg Gary	Officer	Aug 26 '24	Proposed Sale	2.64	14,000	37,000		Aug 26 04:35 PM
White Ted	Officer	Aug 26 '24	Proposed Sale	2.65	34,000	90,100		Aug 26 03:31 PM
Bonaccorso Joe	Officer	Aug 26 '24	Proposed Sale	2.65	34,000	90,100		Aug 26 03:17 PM
Kohler Terry	Officer	Aug 26 '24	Proposed Sale	2.65	30,000	79,500		Aug 26 03:08 PM
White Ted	PRESIDENT AND CEO	Jul 22 '24	Sale	7.06	32,469	229,231	250,121	Jul 23 06:13 PM
White Ted	PRESIDENT AND CEO	Jul 23 '24	Sale	6.98	154	1,075	249,967	Jul 23 06:13 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Jul 22 '24	Sale	7.06	25,461	179,755	106,931	Jul 23 06:12 PM
Bonaccorso Joe	CHIEF COMMERCIAL OFFICER	Jul 23 '24	Sale	6.98	115	803	106,816	Jul 23 06:12 PM
Goldenberg Gary	Chief Medical Officer	Jul 22 '24	Sale	7.06	18,421	130,052	107,836	Jul 23 06:11 PM
Goldenberg Gary	Chief Medical Officer	Jul 23 '24	Sale	6.98	86	600	107,750	Jul 23 06:11 PM
Hayes Christopher G.	CHIEF LEGAL OFFICER	Jul 22 '24	Sale	7.06	21,649	152,842	141,577	Jul 23 06:10 PM
Hayes Christopher G.	CHIEF LEGAL OFFICER	Jul 23 '24	Sale	6.98	91	635	141,486	Jul 23 06:10 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 28 '23	Buy	7.08	126,116	892,901	6,983,408	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 29 '23	Buy	7.24	115,774	838,204	7,099,182	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 27 '23	Buy	7.20	79,726	574,027	6,857,292	Dec 29 05:27 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 22 '23	Buy	6.67	250,000	1,667,500	6,722,914	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 21 '23	Buy	6.17	200,000	1,234,000	6,472,914	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 26 '23	Buy	6.49	54,652	354,691	6,777,566	Dec 26 07:21 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 15 '23	Buy	5.97	500,000	2,985,000	5,538,983	Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 18 '23	Buy	5.41	456,923	2,471,953	5,995,906	Dec 19 05:52 PM
PERCEPTIVE ADVISORS LLC	10% Owner	Dec 19 '23	Buy	5.36	277,008	1,484,763	6,272,914	Dec 19 05:52 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRCA

Verrica Pharmaceuticals Inc

Upgrade your FINVIZ experience